

NEWSLETTER

Volume 9, December 2024

JULY– DECEMBER 2024

NEW INSTITUTIONAL PARTNERS



Hemato Oncology Clinic
Vedanta, Ahmedabad



Medical Trust Hospital,
Kochi



Mahatma Gandhi Cancer
Hospital & Research Institute,
Visakhapatnam

MEMBERSHIP UPDATE

688

Individual members, Consultants,
Physicians, Nurses, Data Entry
Operators and Patients

33

Institutional partners

66TH AMERICAN SOCIETY OF HEMATOLOGY (ASH) ANNUAL MEETING

We are happy to announce that the following studies got accepted as abstracts in ASH-2024:

1. Patterns of Care and Outcomes of Adults \geq 40 Years of Age with Newly Diagnosed Acute Lymphoblastic Leukemia (ALL): A Multicenter Registry Analysis from India.

PI: Dr. Punit Jain

<https://ashpublications.org/blood/article/144/Supplement%201/5858/526702/Patterns-of-Care-and-Outcomes-of-Adults-40-Years>

2. A Phase III Randomized Study of Low Dose Nivolumab Plus AVD or ABVD in Patients with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma (LoNAH Trial).

PI: Dr. Anu Korula

<https://www.hemecancer.org/abstracts.php>

3. Impact of consolidation radiotherapy in bulky Diffuse Large B Cell Lymphoma by PET based response assessment.

PI: Dr. Chandran K Nair

<https://www.hemecancer.org/abstracts.php>

4TH HCC ANNUAL MEETING

The 4th HCC Annual Meeting was held on October 18-19, 2024, at the National Cancer Institute, AIIMS, Jhajjar, focusing on advances in hematological cancer research, treatment standardization, and collaborative efforts to improve patient care.

Day 1 Highlights:

- A Data Entry Operator (DEO) Workshop addressed data management challenges and trained operators on the new Case Report Forms (CRFs), improving registries for AML, CML, ALL, and Lymphoma.
- Investigator sessions presented practice-changing updates, highlighting innovative treatments and research in leukemia and lymphoma.

Day 2 Highlights:

- Discussions emphasized patient advocacy, focusing on improving support systems, access to resources, and addressing disparities in care.
- The HCC Database updates showcased trends in demographics and treatment outcomes, and solutions were proposed for missing and inconsistent data.

Working Groups:

- Refined clinical trial protocols, including CRF standardization and data quality checks.
- Discussed prospective studies in AML, CML, ALL, and Lymphoma, prioritizing cost-effective and regionally relevant treatment strategies.

We sincerely thank the National Cancer Institute for hosting the HCC Annual Meeting, providing logistics for the meeting conduct and on-campus accommodation, contributing to a seamless and successful event





EDUCATION & TRAINING

PATIENT ADVOCACY SESSION

- HCC's Patient Advocacy Group has been formed in January 2023 and the team has launched an online support group for patients, survivors and caregivers.
- The Patient Support Group meetings are held on third Saturday of every month at 11.00am.
- Eighteen patient support group sessions have been conducted so far.

We are deeply grateful to all the experts for dedicating their time and conducting the sessions for patients and caregivers

- Support group meeting topic since July 2024:

| | |
|---|---|
| Topic: Nutrition during treatment of Blood Cancer Speaker: Ms Rupal Manoj Shah Dietician, ICMR, NIRRH |  |
| Topic: Understanding Acute Myeloid Leukemia Speaker: Dr Alok Shetty Assistant Professor Medical Oncology, Tata Memorial Hospital |  |
| Topic: Understanding Chronic Myeloid Leukemia Speaker: Dr Reashma Roshan Associate Professor Dept of Clinical Hematology and BMT, SKIMS |  |
| Topic: Understanding Acute Lymphoblastic Leukemia Speaker: Dr Hasmukh Jain Professor Medical Oncology, Tata Memorial Hospital |  |
| Topic: Understanding Acute Promyelocytic Leukemia Speaker: Dr Sushil Selvarajan Associate Professor, Department of Hematology Christian Medical College, Vellore |  |

EDUCATION & TRAINING

NURSING WEBINARS

- HCC nurses group had initiated an education program to enhance knowledge since January 2021.
- Webinars are held on the last Tuesday of every month at 3.00pm.
- Thirty-one nursing webinars have been conducted so far.

Thank you, team! We are deeply grateful to all the experts for dedicating their time and conducting the sessions for nurses.

- Nursing Webinars conducted since July 24:

| | |
|---|---|
| <p>Topic: Compassion in Action: Tools for Combating Compassion Fatigue in Nursing Speaker: Ms. Vanashree CBCT Compassion Training</p> |  |
| <p>Topic: Treatment of Acute Myeloid Leukemia Speaker: Dr Alok Shetty Assistant Professor Medical Oncology Tata Memorial Hospital</p> |  |
| <p>Topic: Treatment of Lymphoma Speaker: Dr Chandran K Nair Professor Medical Oncology Malabar Cancer Centre</p> |  |
| <p>Topic: Treatment of Acute Lymphoblastic Leukemia Speaker: Dr Swaminathan Assistant Professor Medical Oncology JIPMER, Puducherry</p> |  |
| <p>Topic: Treatment of Acute Promyelocytic Leukemia Speaker: Dr. Priyanka Samal Professor and HOD of Department of Clinical Hematology, Institute of Medical Sciences & SUM Hospital, Bhubaneswar</p> |  |

DATA ENTRY OPERATOR TRAINING (DEO)

- We are assessing and identifying areas where the DEOs need training and accordingly offering customized training session.
- DEO Training Session conducted since July 2024:

Topic: HCC DEO Training for the updated ALL CRF
Speaker: Dr. Punit Jain
Consultant Hematologist, Program coordinator, BMT physician
Apollo Hospital, Navi Mumbai



The DEO Training sessions conducted in the 4th HCC Annual Meeting on 18th October, 2024 are:

- Review of AML CRF and data entry process conducted by Dr. Uday Kulkarni
- Review of CML CRF and data entry process conducted by Dr. Rajan Kapoor
- Review of ALL CRF and data entry process conducted by Dr. Manju Sengar
- Review of Lymphoma CRF and data entry process conducted by Dr. Chandran Nair

ONGOING CLINICAL TRIALS

Phase III open labeled randomized controlled study to evaluate the optimal dose of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. (HCC-APL22 DOSA Study)

- CTRI No.: CTRI/2023/09/057990
- Sample size: 280 patients (140 patients in each arm)
- Study duration: 7 years
- Indication: Patients with newly diagnosed with Acute Promyelocytic Leukemia and age more than 15 years at diagnosis.
- Update: Total 15 patients enrolled from CMC Vellore and JIPMER

Induction Related Mortality Score in Acute Myeloid Leukemia: Prospective Validation Study (HCC pRISM-S)

- CTRI Registration No: CTRI/2020/07/026450
- Update: Enrolment is complete, 3 years follow up data collection is going on; Source data verification and data validation is completed; Data analysis and manuscript work is on-going; Initial data was presented as an abstract in ASH 2022

Cont..

Ongoing Clinical Trials

A phase III randomized study to compare a risk-stratified and response-adapted strategy to ABVD regimen in adolescents and adults with advanced-stage Hodgkin lymphoma.

- CTRI Registration no.: CTRI/2020/12/030132
- Sample size: 200 patients
- Study duration: 4 years accrual, 3 years follow-up since last enrolled patient and 10 years for long-term follow-up phase since the last patient is enrolled.
- Update: Long term follow up ongoing

A phase III RCT comparing AVD + low dose nivolumab versus ABVD using risk - adapted strategy in newly diagnosed advanced stage classical Hodgkin Lymphoma (LoNAH Study).

- CTRI Registration no.: CTRI/2024/03/063942
- Sample size: 280 patients (140 patients in each arm)
- Study duration: 3 years
- Indication: Patients with newly diagnosed advanced stage HL with a PET scan done within previous one month and age above 12 years
- Update: Total patients enrolled till date are 40:- 36 patients from CMC, Vellore and 4 patients from JIPMER

Patterns of Care and Outcomes of Adults \geq 40 Years of Age with Newly Diagnosed Acute Lymphoblastic Leukemia (ALL): A Multicenter Registry Analysis from India

- Update: Source data verification (SDV) ongoing; published in ASH-2024-
<https://ashpublications.org/blood/article/144/Supplement%201/5858/526702/Patterns-of-Care-and-Outcomes-of-Adults-40-Years>

COVID-19 with Hematological Cancers Registry of India (CHCRI Study)

- Update: Enrolment is complete, 5-year follow-up data collection is going on; Data validation is in progress; Analysis will be done after completion of long term follow up; Initial data has been published in Blood Cancer Journal

Upcoming Clinical Trial

A multi-centre Phase III randomized control trial to test the efficacy of targeted agents during induction and a response-adapted consolidation in adolescents and young adult patients with de-novo ALL (TARGET Trial)

- Sample size: 812 in B-ALL cohort and 268 in T-ALL cohort
- Time Perspective: Prospective; 3 years accrual followed by 3 years Follow-up
- Update: Total participation of 8 centres (CMC Vellore, Amala Institute, TMC Kolkata, SKIMS, JIPMER, Amrita Institute, Cancer Institute WIA Chennai and TMH Mumbai), all study documents are finalized, IEC approval under process for each site.

STUDY STATUS

HCC has completed 9 observational studies and 1 prospective study till date

HCC DISEASE WORKING GROUP

Introducing Our Disease Working Group Leaders!

Our expert committee members are at the forefront of advancing hematological cancer research, working together to make meaningful progress in treatment and care. We sincerely thank them for their dedication and unwavering commitment to this important mission.

ACUTE MYELOID LEUKEMIA (AML)



Chair: Dr. Smita Kayal
JIPMER, Puducherry




Co-Chair: Dr. Uday Kulkarni
Christian Medical College, Vellore



Member: Dr. Nikita Mehra
Cancer Institute (WIA), Chennai



Member: Dr. Santhosh Kumar
Ramaiah Medical College Hospital,
Bengaluru



Member: Dr. Priyanka Samal
Institute of Medical Sciences & SUM
Hospital, Bhubaneswar

ACUTE LYMPHOBLASTIC LEUKEMIA (ALL)



Chair: Dr. Prasanth Ganesan
JIPMER, Puducherry



Co-Chair: Dr. Hasmukh Jain- Tata
Memorial Centre, Mumbai



Member: Dr. Rashmi Palaserry
Ramaiah Medical College Hospital,
Bengaluru



Member: Dr. Afaq Ahmad
Sher-i-Kashmir Institute of Medical
Sciences, Srinagar



Member: Dr. Punit Jain- Apollo
Hospital, Navi Mumbai

CHRONIC MYELOID LEUKEMIA (CML)



Chair: Dr. Aby Abraham
Christian Medical College, Vellore



Co-Chair: Dr. Rajan Kapoor
Army Hospital R&R, Department Of
Hematology, New Delhi



Member: Dr. Suvir Singh
Dayanand Medical College,
Ludhiana



Member: Dr. Sandeep
Nemani- Shri
Siddhivinayak Ganapati
Cancer Hospital, Miraj,
Maharashtra



Member: Dr. Sanjeevan
Sharma
Army Hospital R&R,
Department Of Hematology,
New Delhi



Member: Dr. Prasanth
Parameswaran
MVR Cancer Centre and
Research Institute (MVRCCRI),
Calicut

LYMPHOMA



Chair: Dr. Anu Korula
Christian Medical College, Vellore



Co-Chair: Dr. Chandran Nair
Malabar Cancer Centre, Thalassery



Member: Dr. Lingaraj Nayak
Tata Memorial Centre, Mumbai



Member: Dr. Biswajit Dubashi
JIPMER, Puducherry



Member: Dr. Mobin Paul
Rajagiri Hospital, Kochi

MDS/MPN



Chair: Dr. Joseph John
Christian Medical College, Ludhiana



Co-Chair: Dr. Chepsy Philip
BCMCH, Thiruvalla



Member: Dr. Renjith Varghese
Commando Hospital, Pune



Member: Dr. Sushil Selvarajan
Christian Medical College, Vellore



Member: Dr. Alok Shetty
Tata Memorial Centre, Mumbai

HCC EXPRESSES HEARTFELT GRATITUDE TO THE NATIONAL CANCER GRID , AS WELL AS TO ALL THE INDIVIDUAL AND CORPORATE SUPPORTERS FOR THEIR GENEROUS CONTRIBUTIONS AND THE UNWAVERING SUPPORT TOWARDS THE REGISTRY

**WISHING ALL OUR PARTNERS, MEMBERS, AND SUPPORTERS A
HAPPY AND PROSPEROUS NEW YEAR**

**INDIVIDUALS AND INSTITUTIONS WITH AN INTEREST IN HEMATOLOGICAL MALIGNANCIES CAN BECOME MEMBERS,
REGISTER : [HTTP://HEMECANCER.ORG/MEMBERSHIP.PHP](http://hemecancer.org/membership.php)**

